Cytomed therapeutics limited (GDTC) 2025Q2 financial report shows net profit of -882.3K USD, with a YoY growth rate of -9.20%, slightly lower than the same period last year, indicating profitability is starting to weaken and operational pressure is increasing. It is recommended to keep tracking revenue, cash flow, and expense structure, and use Growin AI Value Analysis to observe whether the company can adjust its operating strategy. If the core business remains stable, short-term challenges are still manageable.